Endoscopic mucosal resection versus esophagectomy for intramucosal adenocarcinoma in the setting of barrett's esophagus
- PMID: 28342132
- DOI: 10.1007/s00464-017-5479-z
Endoscopic mucosal resection versus esophagectomy for intramucosal adenocarcinoma in the setting of barrett's esophagus
Abstract
Background: Esophagectomy has been the standard of care for patients with intramucosal adenocarcinoma (IMC) in the setting of Barrett's esophagus. It is, however, associated with significant post-operative morbidity and mortality. Endoscopic mucosal resection (EMR) offers a minimally invasive approach with lesser morbidity. This study investigates the transition from esophagectomy to EMR for IMC with respect to eradication rates, post-operative morbidity, and long-term survival.
Methods: Patients diagnosed with IMC from 2005 to 2013 were identified retrospectively. Beginning in 2009, preferred initial therapy for IMC transitioned from esophagectomy to EMR. Esophagectomy was performed either through a transthoracic or transhiatal technique. EMR was repeated until resolution of IMC on pathology or progression of disease. Continuous data are expressed as mean (SD) and analyzed using Student's t test. Categorical data are presented as number (%) and analyzed using Fisher's exact test.
Results: We identified 23 patients; 12 patients underwent esophagectomy and 11 patients underwent EMR as initial therapy. Patients were similar with respects to age, gender, and comorbidity index. Most tumors arose from short segment (vs long segment) Barrett's (esophagectomy: 9 (75%) vs. EMR: 10 (91%), p = 0.59) and one patient in each group had superficial invasion into the submucosa (T1sm1), the remainder having mucosal disease. Esophagectomy was associated with 7 (58%) minor complications and 2 (17%) major complications (respiratory failure, anastomotic leak), whereas there were no complications related to EMR (p < 0.01). EMR successfully eradicated IMC in 10 patients (91%) with one progressing to esophagectomy. Patients required 2 (1) endoscopies to achieve eradication. There was one mortality in each group on long-term follow-up (log-rank test, p = 0.62).
Conclusions: EMR was successful in eradicating IMC in 10/11 patients with similar long-term recurrence and mortality to esophagectomy patients. Patients with IMC may benefit from EMR as initial therapy by obviating the need for a complex and morbid operation.
Keywords: Barrett’s esophagus; Early esophageal cancer; Endoscopic mucosal resection; Esophagectomy; Intramucosal carcinoma.
Similar articles
-
Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.Am J Gastroenterol. 2009 Nov;104(11):2684-92. doi: 10.1038/ajg.2009.465. Epub 2009 Aug 18. Am J Gastroenterol. 2009. PMID: 19690526
-
Ten-year follow-up of endoscopic mucosal resection versus esophagectomy for esophageal intramucosal adenocarcinoma in the setting of Barrett's esophagus: a Canadian experience.Surg Endosc. 2023 Nov;37(11):8735-8741. doi: 10.1007/s00464-023-10318-0. Epub 2023 Aug 10. Surg Endosc. 2023. PMID: 37563345
-
Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma.Endoscopy. 2007 Dec;39(12):1086-91. doi: 10.1055/s-2007-966788. Epub 2007 Aug 15. Endoscopy. 2007. PMID: 17701854
-
High-grade dysplasia and intramucosal adenocarcinoma in Barrett's esophagus: the role of esophagectomy in the era of endoscopic eradication therapy.Curr Opin Gastroenterol. 2012 Jul;28(4):362-9. doi: 10.1097/MOG.0b013e328353e346. Curr Opin Gastroenterol. 2012. PMID: 22517568 Review.
-
[Limited surgical resection versus local endoscopic therapy of early cancers of the esophagogastric junction].Zentralbl Chir. 2006 Apr;131(2):97-104. doi: 10.1055/s-2006-921551. Zentralbl Chir. 2006. PMID: 16612774 Review. German.
Cited by
-
Endoscopic resection versus esophagectomy for early esophageal cancer: a meta-analysis.Transl Cancer Res. 2021 Jun;10(6):2653-2662. doi: 10.21037/tcr-21-182. Transl Cancer Res. 2021. PMID: 35116578 Free PMC article.
-
Endoscopic therapy for Barrett's esophagus and early esophageal cancer: Where do we go from here?World J Gastrointest Endosc. 2018 Sep 16;10(9):165-174. doi: 10.4253/wjge.v10.i9.165. World J Gastrointest Endosc. 2018. PMID: 30283599 Free PMC article. Review.
-
Endoscopic Treatment Versus Esophagectomy for Early-Stage Esophageal Cancer: a Population-Based Study Using Propensity Score Matching.J Gastrointest Surg. 2017 Dec;21(12):1977-1983. doi: 10.1007/s11605-017-3563-2. Epub 2017 Oct 13. J Gastrointest Surg. 2017. PMID: 29030780
-
Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy.Gastroenterology. 2018 Jan;154(2):421-436. doi: 10.1053/j.gastro.2017.07.041. Epub 2017 Aug 2. Gastroenterology. 2018. PMID: 28778650 Free PMC article. Review.
-
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett's oesophagus and stage I oesophageal adenocarcinoma.Gut. 2024 May 10;73(6):897-909. doi: 10.1136/gutjnl-2023-331557. Gut. 2024. PMID: 38553042 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical